"Hypogonadism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Descriptor ID |
D007006
|
| MeSH Number(s) |
C19.391.482
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hypogonadism".
Below are MeSH descriptors whose meaning is more specific than "Hypogonadism".
This graph shows the total number of publications written about "Hypogonadism" by people in this website by year, and whether "Hypogonadism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 0 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 7 | 0 | 7 |
| 2013 | 7 | 1 | 8 |
| 2014 | 14 | 2 | 16 |
| 2015 | 9 | 3 | 12 |
| 2016 | 10 | 2 | 12 |
| 2017 | 11 | 3 | 14 |
| 2018 | 7 | 4 | 11 |
| 2019 | 5 | 2 | 7 |
| 2020 | 10 | 2 | 12 |
| 2021 | 9 | 3 | 12 |
| 2022 | 5 | 0 | 5 |
| 2023 | 6 | 0 | 6 |
| 2024 | 4 | 1 | 5 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypogonadism" by people in Profiles.
-
Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e814-e826.
-
Testosterone Modulation of Muscle Transcriptomic Profile During Lifestyle Therapy in Older Men with Obesity and Hypogonadism. J Cachexia Sarcopenia Muscle. 2025 Feb; 16(1):e13697.
-
PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/?-CATENIN Pathway in Testosterone-Treated Hypogonadal Men. Biomolecules. 2025 Jan 08; 15(1).
-
Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. J Sex Med. 2024 Dec 01; 21(12):1201-1203.
-
Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2025 May; 13(4):882-893.
-
A PRDM16-driven signal regulates body composition in testosterone-treated hypogonadal men. Front Endocrinol (Lausanne). 2024; 15:1426175.
-
Testosterone levels increase following bariatric surgery - validation of preceding literature in a large-scale population analysis. Andrology. 2025 Mar; 13(3):431-438.
-
Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
-
Attention-deficit hyperactivity disorder medication use is associated with testosterone hypofunction-results from a national claims database analysis. Int J Impot Res. 2024 Jun; 36(4):403-407.
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.